source: qrda/C0Q/trunk/kids/C0QDATA_1_0_0_T1.KID@ 1482

KIDS Distribution saved on Feb 17, 2012@16:48:29
only the C0Q QUALITY MEASURE file with data
**KIDS**:C0QDATA*1.0*1^

**INSTALL NAME**
C0QDATA*1.0*1
"BLD",7923,0)
C0QDATA*1.0*1^^0^3120217^n
"BLD",7923,4,0)
^9.64PA^1130580001.101^1
"BLD",7923,4,1130580001.101,0)
1130580001.101
"BLD",7923,4,1130580001.101,222)
y^y^f^^n^^y^m^y
"BLD",7923,4,"B",1130580001.101,1130580001.101)

"BLD",7923,6.3)
1
"BLD",7923,"KRN",0)
^9.67PA^779.2^20
"BLD",7923,"KRN",.4,0)
.4
"BLD",7923,"KRN",.401,0)
.401
"BLD",7923,"KRN",.402,0)
.402
"BLD",7923,"KRN",.403,0)
.403
"BLD",7923,"KRN",.5,0)
.5
"BLD",7923,"KRN",.84,0)
.84
"BLD",7923,"KRN",3.6,0)
3.6
"BLD",7923,"KRN",3.8,0)
3.8
"BLD",7923,"KRN",9.2,0)
9.2
"BLD",7923,"KRN",9.8,0)
9.8
"BLD",7923,"KRN",19,0)
19
"BLD",7923,"KRN",19.1,0)
19.1
"BLD",7923,"KRN",101,0)
101
"BLD",7923,"KRN",409.61,0)
409.61
"BLD",7923,"KRN",771,0)
771
"BLD",7923,"KRN",779.2,0)
779.2
"BLD",7923,"KRN",870,0)
870
"BLD",7923,"KRN",8989.51,0)
8989.51
"BLD",7923,"KRN",8989.52,0)
8989.52
"BLD",7923,"KRN",8994,0)
8994
"BLD",7923,"KRN","B",.4,.4)

"BLD",7923,"KRN","B",.401,.401)

"BLD",7923,"KRN","B",.402,.402)

"BLD",7923,"KRN","B",.403,.403)

"BLD",7923,"KRN","B",.5,.5)

"BLD",7923,"KRN","B",.84,.84)

"BLD",7923,"KRN","B",3.6,3.6)

"BLD",7923,"KRN","B",3.8,3.8)

"BLD",7923,"KRN","B",9.2,9.2)

"BLD",7923,"KRN","B",9.8,9.8)

"BLD",7923,"KRN","B",19,19)

"BLD",7923,"KRN","B",19.1,19.1)

"BLD",7923,"KRN","B",101,101)

"BLD",7923,"KRN","B",409.61,409.61)

"BLD",7923,"KRN","B",771,771)

"BLD",7923,"KRN","B",779.2,779.2)

"BLD",7923,"KRN","B",870,870)

"BLD",7923,"KRN","B",8989.51,8989.51)

"BLD",7923,"KRN","B",8989.52,8989.52)

"BLD",7923,"KRN","B",8994,8994)

"DATA",1130580001.101,1,0)
M1^41^40^2.16.840.1.113883.3.249.11.2
"DATA",1130580001.101,1,1)
CMS Measure #1: Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus
"DATA",1130580001.101,1,4)
PQRI-1
"DATA",1130580001.101,1,5)
Hemoglobin A1c Poor Control in Diabetes Mellitus
"DATA",1130580001.101,1,6,0)
^^2^2^3101013^
"DATA",1130580001.101,1,6,1,0)
Percentage of patients 18 through 75 years with diabetes melli
"DATA",1130580001.101,1,6,2,0)
tus who had most recent hemoglobin A1C greater than 9.0%
"DATA",1130580001.101,2,0)
M5^47^46^2.16.840.1.113883.3.249.11.5
"DATA",1130580001.101,2,1)
CMS Measure #5: Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
"DATA",1130580001.101,2,4)
PQRI-5
"DATA",1130580001.101,2,5)
Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
"DATA",1130580001.101,2,6,0)
^^2^2^3101013^
"DATA",1130580001.101,2,6,1,0)
Percentage of patients 18 years and older with a diagnosis of 
"DATA",1130580001.101,2,6,2,0)
heart failure and LVSD who were prescribed an ACE inhbitor or ARB therapy
"DATA",1130580001.101,3,0)
M112^26^25^2.16.840.1.113883.3.249.11.9
"DATA",1130580001.101,3,1)
Measure #112: Preventive Care and Screening: Screening Mammography
"DATA",1130580001.101,3,4)
PQRI-112
"DATA",1130580001.101,3,5)
Screening Mammography
"DATA",1130580001.101,3,6,0)
^1130580001.111^2^2^3101014^^
"DATA",1130580001.101,3,6,1,0)
Percentage of womaen aged 40 through 69 years who had a mammog
"DATA",1130580001.101,3,6,2,0)
ram to screen for breast cancer within 24 months
"DATA",1130580001.101,4,0)
M124^33^33^2.16.840.1.113883.3.249.11.11
"DATA",1130580001.101,4,1)
Measure #124: Health Information Technology (HIT): Adoption/Use of Electronic Health Records
"DATA",1130580001.101,4,4)
PQRI-124
"DATA",1130580001.101,4,5)
Adoption/Use of Electronic Health Records (EHR)
"DATA",1130580001.101,4,6,0)
^^3^3^3101013^
"DATA",1130580001.101,4,6,1,0)
Documents whether provider has adopted and is using health inf
"DATA",1130580001.101,4,6,2,0)
ormation technology. To qualify, the provider must havea adopted and be 
"DATA",1130580001.101,4,6,3,0)
using a certified/qualified electronic health record (EHR)
"DATA",1130580001.101,5,0)
M128^58^31^2.16.840.1.113883.3.249.11.54
"DATA",1130580001.101,5,1)
Measure #128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
"DATA",1130580001.101,5,4)
PQRI-128
"DATA",1130580001.101,5,5)
Body Mass Index (BMI) Screening and Follow-Up
"DATA",1130580001.101,5,6,0)
^1130580001.111^5^5^3101014^^
"DATA",1130580001.101,5,6,1,0)
Percentage of patients aged 18 yesrs and older with a calculate BMI in 
"DATA",1130580001.101,5,6,2,0)
the past 6 months or during the current visit documented in the medical 
"DATA",1130580001.101,5,6,3,0)
record and if the most recent BMI is ourtide parameters, a follow-up plan 
"DATA",1130580001.101,5,6,4,0)
is documented. Ages 65 and older BMI equal to or greater than 30 or less 
"DATA",1130580001.101,5,6,5,0)
than 22 and ages 18-64, BMI greater than or equal to 25 or less than 18.5
"DATA",1130580001.101,6,0)
M47^20^48^2.16.840.1.113883.3.249.11.52
"DATA",1130580001.101,6,1)
Measure #47: Advance Care Plan
"DATA",1130580001.101,6,4)
PQRI-47
"DATA",1130580001.101,6,5)
Advance Care Plan
"DATA",1130580001.101,6,6,0)
^1130580001.111^5^5^3101014^^^
"DATA",1130580001.101,6,6,1,0)
Percentage of patients age 65 and older who have an advanced care plan or 
"DATA",1130580001.101,6,6,2,0)
surrogate decision maker documented in the medical record or documented 
"DATA",1130580001.101,6,6,3,0)
in the medical record that an advance care plan was discussed but the 
"DATA",1130580001.101,6,6,4,0)
patient did not wish or was not able to name a surrogate decision maker 
"DATA",1130580001.101,6,6,5,0)
or provide an advance care plan.
"DATA",1130580001.101,7,0)
M48^24^23^2.16.840.1.113883.3.249.11.53
"DATA",1130580001.101,7,1)
Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
"DATA",1130580001.101,7,4)
PQRI-48
"DATA",1130580001.101,7,5)
Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
"DATA",1130580001.101,7,6,0)
^^3^3^3101013^
"DATA",1130580001.101,7,6,1,0)
Percentage of patients equal to or older than 65 years of age at the 
"DATA",1130580001.101,7,6,2,0)
beginning of the measurement perion who were assesed for the presence or 
"DATA",1130580001.101,7,6,3,0)
absence of urinary incontinence within 12 months
"DATA",1130580001.101,8,0)
M2^43^42^2.16.840.1.113883.3.249.11.3
"DATA",1130580001.101,8,1)
Measure #2: Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
"DATA",1130580001.101,8,4)
PQRI-2
"DATA",1130580001.101,8,5)
Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
"DATA",1130580001.101,8,6,0)
^^2^2^3101013^
"DATA",1130580001.101,8,6,1,0)
Percentage of patients 18 through 75 years with diabetes melli
"DATA",1130580001.101,8,6,2,0)
tus who had most recent LDL-C level in control (less than 100 mg./dL)
"DATA",1130580001.101,9,0)
M3^45^44^2.16.840.1.113883.3.249.11.4
"DATA",1130580001.101,9,1)
CMS Measure #3: Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus - QRDA Cat I template
"DATA",1130580001.101,9,4)
PQRI-3
"DATA",1130580001.101,9,5)
High Blood Pressure Control in Diabetes Mellitus
"DATA",1130580001.101,9,6,0)
^^2^2^3101013^
"DATA",1130580001.101,9,6,1,0)
Percentage of patients 18 through 75 years with diabetes melli
"DATA",1130580001.101,9,6,2,0)
tus who had most recent blood pressure in control (less than 140/80 mmHg)
"DATA",1130580001.101,10,0)
M7^35^34^2.16.840.1.113883.3.249.11.6
"DATA",1130580001.101,10,1)
CMS Measure #7: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)
"DATA",1130580001.101,10,4)
PQRI-7
"DATA",1130580001.101,10,5)
Percentage of patients 18 aged 18 years and older wit a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy
"DATA",1130580001.101,10,6,0)
^^3^3^3101013^
"DATA",1130580001.101,10,6,1,0)
Percentage of patients aged 18 years and older with a diagnosis of 
"DATA",1130580001.101,10,6,2,0)
coronary artery disease and a prior MI who where prescribed beta-blocker 
"DATA",1130580001.101,10,6,3,0)
therapy
"DATA",1130580001.101,11,0)
M110^81^80^2.16.840.1.113883.3.249.11.7
"DATA",1130580001.101,11,1)
Measure #110: Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years
"DATA",1130580001.101,11,4)
PQRI-110
"DATA",1130580001.101,11,5)
Influenza Immunization for Patients >= 50 Years
"DATA",1130580001.101,11,6,0)
^1130580001.111^2^2^3101014^^
"DATA",1130580001.101,11,6,1,0)
Percentage of patients aged 50 years and older who received an
"DATA",1130580001.101,11,6,2,0)
 influenza immunization during the flu season (September through February)
"DATA",1130580001.101,12,0)
M111^71^68^2.16.840.1.113883.3.249.11.8
"DATA",1130580001.101,12,1)
Measure #111: Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older
"DATA",1130580001.101,12,4)
PQRI-111
"DATA",1130580001.101,12,5)
Pneumonia Vaccination for Patients 65 Years and Older
"DATA",1130580001.101,12,6,0)
^^2^2^3101013^
"DATA",1130580001.101,12,6,1,0)
Percentage of patients afed 65 years and older who have ever r
"DATA",1130580001.101,12,6,2,0)
eceived a pneumoccal vaccine
"DATA",1130580001.101,13,0)
M113^67^66^2.16.840.1.113883.3.249.11.10
"DATA",1130580001.101,13,1)
Measure #113: Preventive Care and Screening: Colorectal Cancer Screening
"DATA",1130580001.101,13,4)
PQRI-113
"DATA",1130580001.101,13,5)
Colorectal Cancer Screening
"DATA",1130580001.101,13,6,0)
^^2^2^3101013^
"DATA",1130580001.101,13,6,1,0)
Percentage of patients aged 50 through 80 who received the app
"DATA",1130580001.101,13,6,2,0)
ropriate colorectal cancer screening
"DATA",1130580001.101,14,0)
M39^65^64^2.16.840.1.113883.3.249.11.51
"DATA",1130580001.101,14,1)
Measure #39: Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
"DATA",1130580001.101,14,4)
PQRI-39
"DATA",1130580001.101,14,5)
Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
"DATA",1130580001.101,14,6,0)
^^3^3^3101013^
"DATA",1130580001.101,14,6,1,0)
Percentage of patients who had a DXA measurement ordered or pe
"DATA",1130580001.101,14,6,2,0)
rformed at least once since age 60 or pharmacologic therapy prescribed 
"DATA",1130580001.101,14,6,3,0)
within 12 months before the end of the measurement period
"DATA",1130580001.101,16,0)
M173^50^49^2.16.840.1.113883.3.249.11.55
"DATA",1130580001.101,16,1)
Measure #173: Preventive Care and Screening: Unhealthy Alcohol Use - Screening
"DATA",1130580001.101,16,4)
PQRI-173
"DATA",1130580001.101,16,5)
Preventive Care and Screening: Unhealthy Alcohol Use - Screening
"DATA",1130580001.101,16,6,0)
^^2^2^3101013^
"DATA",1130580001.101,16,6,1,0)
Percentage of patients aged 18 years and older who were screen
"DATA",1130580001.101,16,6,2,0)
ed for unhealthy alcohol use using a systematic method within 24 months
"DATA",1130580001.101,17,0)
M0013^52^77^2.16.840.1.113883.3.249.11.56
"DATA",1130580001.101,17,1)
Measure #0013: Hypertension (HTN): Blood Pressure Measurement - QRDA Cat I template
"DATA",1130580001.101,17,4)
PQRI-13
"DATA",1130580001.101,17,5)
Hypertension (HTN): Blood Pressure Measurement
"DATA",1130580001.101,17,6,0)
^1130580001.111^3^3^3110412^^
"DATA",1130580001.101,17,6,1,0)
Percentage of patients aged 18 years and older with a diagnosi
"DATA",1130580001.101,17,6,2,0)
s of hypertension in the beginning of the measurement period with a blood 
"DATA",1130580001.101,17,6,3,0)
pressure recorded
"DATA",1130580001.101,18,0)
M0022^73^61^2.16.840.1.113883.3.249.11.57
"DATA",1130580001.101,18,1)
Measure #0022: Drugs to be avoided in the Elderly
"DATA",1130580001.101,18,4)
PQRI-22
"DATA",1130580001.101,18,5)
Drugs to be avoided in the elderly
"DATA",1130580001.101,18,6,0)
^^2^2^3101013^
"DATA",1130580001.101,18,6,1,0)
Percentage of patients aged 65 years and older who received at least one 
"DATA",1130580001.101,18,6,2,0)
drug to be avoided in the elderly in the measurement period
"DATA",1130580001.101,19,0)
M0028^79^78^2.16.840.1.113883.3.249.11.59
"DATA",1130580001.101,19,1)
Measure #0028: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
"DATA",1130580001.101,19,4)
PQRI-28
"DATA",1130580001.101,19,5)
Preventive care and Screening: Tobacco Use: Screening and Cessation Intervention
"DATA",1130580001.101,19,6,0)
^^4^4^3101013^
"DATA",1130580001.101,19,6,1,0)
Percentage of patients aged 18 years of older who were screene
"DATA",1130580001.101,19,6,2,0)
d about tobacco use at least once during the two year measurement period 
"DATA",1130580001.101,19,6,3,0)
AND who received smoking cessation counseling if identified as a tobacco 
"DATA",1130580001.101,19,6,4,0)
user
"DATA",1130580001.101,20,0)
M0038^85^84^2.16.840.1.113883.3.249.11.60
"DATA",1130580001.101,20,1)
Measure #0038: Childhood Immunization Status
"DATA",1130580001.101,20,4)
PQRI-38
"DATA",1130580001.101,20,5)
Childhood immumnization status
"DATA",1130580001.101,20,6,0)
^^4^4^3101013^
"DATA",1130580001.101,20,6,1,0)
Percentage of children who turn two years of age during the me
"DATA",1130580001.101,20,6,2,0)
asurement period who have had 4 DTaP/DT, 3 IPV, 1 MMR and 3 H influenza 
"DATA",1130580001.101,20,6,3,0)
type B, 3 hepatitis B, 1 chicken pox vaccine (VZV) and 4 pneumoccal 
"DATA",1130580001.101,20,6,4,0)
conjugate vaccines by their second birthday
"DATA",1130580001.101,21,0)
M0024^72^70
"DATA",1130580001.101,22,0)
TEST M0028A^107^106^2.16.840.1.113883.3.249.11.59
"DATA",1130580001.101,22,1)
Measure #0028: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
"DATA",1130580001.101,22,4)
PQRI-28
"DATA",1130580001.101,22,5)
Preventive care and Screening: Tobacco Use: Screening and Cessation Intervention
"DATA",1130580001.101,22,6,0)
^1130580001.111^4^4^3110427^^^^
"DATA",1130580001.101,22,6,1,0)
Percentage of patients aged 18 years of older who were screene
"DATA",1130580001.101,22,6,2,0)
d about tobacco use at least once during the two year measurement period 
"DATA",1130580001.101,22,6,3,0)
AND who received smoking cessation counseling if identified as a tobacco 
"DATA",1130580001.101,22,6,4,0)
user
"DATA",1130580001.101,23,0)
MU HOS NQF 0495^53^135
"DATA",1130580001.101,23,1)
ED THROUGHPUT ARRIVAL TO DEPARTURE
"DATA",1130580001.101,23,5)
ED THROUGHPUT ARRIVAL TO DEPARTURE
"DATA",1130580001.101,23,6,0)
^1130580001.111^3^3^3110430^^^^
"DATA",1130580001.101,23,6,1,0)
Median time from emergency department arrival to time of departure from 
"DATA",1130580001.101,23,6,2,0)
the emergency room for patients admitted to the facility from the
"DATA",1130580001.101,23,6,3,0)
emergency department
"DATA",1130580001.101,23,7)
NQF0495
"DATA",1130580001.101,24,0)
MU HOS NQF 0497^54^94
"DATA",1130580001.101,24,1)
ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
"DATA",1130580001.101,24,5)
ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
"DATA",1130580001.101,24,6,0)
^^3^3^3110430^
"DATA",1130580001.101,24,6,1,0)
Median time from admit decision time to time of departure from the 
"DATA",1130580001.101,24,6,2,0)
emergency department of emergency department patients admitted to 
"DATA",1130580001.101,24,6,3,0)
inpatient status
"DATA",1130580001.101,24,7)
NQF0497
"DATA",1130580001.101,25,0)
MU HOS NQF 0435^55^56
"DATA",1130580001.101,25,1)
Ischemic stroke.Discharge on anti-thrombotics  
"DATA",1130580001.101,25,5)
 Ischemic stroke.Discharge on anti-thrombotic
"DATA",1130580001.101,25,6,0)
^^2^2^3110430^
"DATA",1130580001.101,25,6,1,0)
Ischemic stroke patients prescribed antithrombotic therapy at hospital 
"DATA",1130580001.101,25,6,2,0)
discharge
"DATA",1130580001.101,25,7)
NQF0435
"DATA",1130580001.101,26,0)
MU HOS NQF 0436^57^58
"DATA",1130580001.101,26,1)
 Ischemic stroke.Anticoagulation for A-fib/flutter
"DATA",1130580001.101,26,5)
Ischemic stroke.Anticoagulation for A-fib/flutter
"DATA",1130580001.101,26,6,0)
^1130580001.111^2^2^3110430^^^
"DATA",1130580001.101,26,6,1,0)
 Ischemic stroke patients with atrial fibrillation/flutter who are 
"DATA",1130580001.101,26,6,2,0)
prescribed anticoagulation therapy at hospital discharge
"DATA",1130580001.101,26,7)
NQF0436
"DATA",1130580001.101,27,0)
MU HOS NQF 0437^59^60
"DATA",1130580001.101,27,1)
 Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
"DATA",1130580001.101,27,5)
Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
"DATA",1130580001.101,27,6,0)
^^3^3^3110430^
"DATA",1130580001.101,27,6,1,0)
Acute ischemic stroke patients who arrive at this hospital within 2 
"DATA",1130580001.101,27,6,2,0)
hours of time last known well and for whom IV t-PA was initiated at this 
"DATA",1130580001.101,27,6,3,0)
hospital within 3 hours of time last known well.
"DATA",1130580001.101,27,7)
NQF0437
"DATA",1130580001.101,28,0)
MU HOS NQF 0438^61^62
"DATA",1130580001.101,28,1)
Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
"DATA",1130580001.101,28,5)
Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
"DATA",1130580001.101,28,6,0)
^^2^2^3110430^
"DATA",1130580001.101,28,6,1,0)
Ischemic stroke patients administered antithrombotic therapy by the 
"DATA",1130580001.101,28,6,2,0)
end of hospital day 2.
"DATA",1130580001.101,28,7)
NQF0438
"DATA",1130580001.101,29,0)
MU HOS NQF 0439^63^64
"DATA",1130580001.101,29,1)
Ischemic stroke.Discharge on statins
"DATA",1130580001.101,29,5)
Ischemic stroke.Discharge on statins
"DATA",1130580001.101,29,6,0)
^^3^3^3110430^
"DATA",1130580001.101,29,6,1,0)
Ischemic stroke patients with LDL > 100 mg/dL, or LDL not measured, or, 
"DATA",1130580001.101,29,6,2,0)
who were on a lipid-lowering medication prior to hospital arrival are
"DATA",1130580001.101,29,6,3,0)
prescribed statin medication at hospital discharge
"DATA",1130580001.101,29,7)
NQF0439
"DATA",1130580001.101,30,0)
MU HOS NQF 0440^65^66
"DATA",1130580001.101,30,1)
Ischemic or hemorrhagic stroke.Stroke education
"DATA",1130580001.101,30,5)
Ischemic or hemorrhagic stroke.Stroke education
"DATA",1130580001.101,30,6,0)
^^5^5^3110430^
"DATA",1130580001.101,30,6,1,0)
Ischemic or hemorrhagic stroke patients or their caregivers who were 
"DATA",1130580001.101,30,6,2,0)
given educational materials during the hospital stay addressing all of the
"DATA",1130580001.101,30,6,3,0)
following: activation of emergency medical system, need for follow-up
"DATA",1130580001.101,30,6,4,0)
after discharge, medications prescribed at discharge, risk factors for
"DATA",1130580001.101,30,6,5,0)
stroke, and warning signs and symptoms of stroke.
"DATA",1130580001.101,30,7)
NQF0440
"DATA",1130580001.101,31,0)
MU HOS NQF 0441^67^68
"DATA",1130580001.101,31,1)
Ischemic or hemorrhagic stroke.Rehabilitation assessment
"DATA",1130580001.101,31,5)
Ischemic or hemorrhagic stroke.Rehabilitation assessment
"DATA",1130580001.101,31,6,0)
^^2^2^3110430^
"DATA",1130580001.101,31,6,1,0)
Ischemic or hemorrhagic stroke patients who were assessed for 
"DATA",1130580001.101,31,6,2,0)
rehabilitation services.
"DATA",1130580001.101,31,7)
NQF0441
"DATA",1130580001.101,32,0)
MU HOS NQF 0371^44^43
"DATA",1130580001.101,32,1)
VTE prophylaxis within 24 hours of arrival  
"DATA",1130580001.101,32,5)
VTE prophylaxis within 24 hours of arrival  
"DATA",1130580001.101,32,6,0)
^^4^4^3110430^
"DATA",1130580001.101,32,6,1,0)
This measure assesses the number of patients who received VTE prophylaxis 
"DATA",1130580001.101,32,6,2,0)
or have documentation why no VTE prophylaxis was given the day of or the 
"DATA",1130580001.101,32,6,3,0)
day after hospital admission or surgery end date for surgeries that start
"DATA",1130580001.101,32,6,4,0)
the day of or the day after hospital admission.
"DATA",1130580001.101,32,7)
NQF0371
"DATA",1130580001.101,33,0)
MU HOS NQF 0372^69^45
"DATA",1130580001.101,33,1)
ICU VTE prophylaxis  
"DATA",1130580001.101,33,5)
ICU VTE prophylaxis
"DATA",1130580001.101,33,6,0)
^^5^5^3110430^
"DATA",1130580001.101,33,6,1,0)
This measure assesses the number of patients who received VTE prophylaxis 
"DATA",1130580001.101,33,6,2,0)
or have documentation why no VTE prophylaxis was given the day of or the 
"DATA",1130580001.101,33,6,3,0)
day after the initial admission (or transfer) to the Intensive Care Unit
"DATA",1130580001.101,33,6,4,0)
(ICU) or surgery end date for surgeries that start the day of or the day
"DATA",1130580001.101,33,6,5,0)
after ICU admission (or transfer).
"DATA",1130580001.101,33,7)
NQF0372
"DATA",1130580001.101,34,0)
MU HOS NQF 0373^70^71
"DATA",1130580001.101,34,1)
Anticoagulation overlap therapy  
"DATA",1130580001.101,34,5)
Anticoagulation overlap therapy
"DATA",1130580001.101,34,6,0)
^^8^8^3110430^
"DATA",1130580001.101,34,6,1,0)
This measure assesses the number of patients diagnosed with confirmed VTE 
"DATA",1130580001.101,34,6,2,0)
who received an overlap of parenteral (intravenous [IV] or subcutaneous 
"DATA",1130580001.101,34,6,3,0)
[subcu]) anticoagulation and warfarin therapy. For patients who received
"DATA",1130580001.101,34,6,4,0)
less than five days of overlap therapy, they must be discharged on both
"DATA",1130580001.101,34,6,5,0)
medications. Overlap therapy must be administered for at least five days
"DATA",1130580001.101,34,6,6,0)
with an international normalized ratio (INR) . 2 prior to discontinuation
"DATA",1130580001.101,34,6,7,0)
of the parenteral anticoagulation therapy or the patient must be
"DATA",1130580001.101,34,6,8,0)
discharged on both medications.
"DATA",1130580001.101,34,7)
NQF0373
"DATA",1130580001.101,35,0)
MU HOS NQF 0374^72^73
"DATA",1130580001.101,35,1)
Platelet monitoring on unfractionated heparin
"DATA",1130580001.101,35,5)
Platelet monitoring on unfractionated heparin
"DATA",1130580001.101,35,6,0)
^^10^10^3110430^
"DATA",1130580001.101,35,6,1,0)
This measure assesses the number of patients diagnosed with confirmed VTE 
"DATA",1130580001.101,35,6,2,0)
who received intravenous (IV) UFH therapy dosages AND had their platelet 
"DATA",1130580001.101,35,6,3,0)
counts monitored using defined parameters such as a nomogram or
"DATA",1130580001.101,35,6,4,0)
protocol This measure assesses the number of patients diagnosed with
"DATA",1130580001.101,35,6,5,0)
confirmed VTE who received intravenous (IV) UFH therapy dosages AND had
"DATA",1130580001.101,35,6,6,0)
their platelet counts monitored using defined parameters such as a
"DATA",1130580001.101,35,6,7,0)
nomogram or protocol This measure assesses the number of patients
"DATA",1130580001.101,35,6,8,0)
diagnosed with confirmed VTE who received intravenous (IV) UFH therapy
"DATA",1130580001.101,35,6,9,0)
dosages AND had their platelet counts monitored using defined parameters
"DATA",1130580001.101,35,6,10,0)
such as a nomogram or protocol
"DATA",1130580001.101,35,7)
NQF0374
"DATA",1130580001.101,36,0)
MU HOS NQF 0375^74^75
"DATA",1130580001.101,36,1)
VTE discharge instructions
"DATA",1130580001.101,36,5)
VTE discharge instructions
"DATA",1130580001.101,36,6,0)
^^11^11^3110430^
"DATA",1130580001.101,36,6,1,0)
This measure assesses the number of patients diagnosed with confirmed VTE 
"DATA",1130580001.101,36,6,2,0)
that are discharged to home, to home with home health, home hospice or 
"DATA",1130580001.101,36,6,3,0)
discharged/transferred to court/law enforcement on warfarin with written 
"DATA",1130580001.101,36,6,4,0)
discharge instructions that address all four criteria: compliance issues,
"DATA",1130580001.101,36,6,5,0)
dietary advice, follow-up This measure assesses the number of patients
"DATA",1130580001.101,36,6,6,0)
diagnosed with confirmed VTE that are discharged to home, to home with
"DATA",1130580001.101,36,6,7,0)
home health, home hospice or discharged/transferred to court/law
"DATA",1130580001.101,36,6,8,0)
enforcement on warfarin with written discharge instructions that address
"DATA",1130580001.101,36,6,9,0)
all four criteria: compliance issues, dietary advice, follow-up
"DATA",1130580001.101,36,6,10,0)
monitoring, and information about the potential for adverse drug 
"DATA",1130580001.101,36,6,11,0)
reactions/interactions.
"DATA",1130580001.101,36,7)
NQF0375
"DATA",1130580001.101,37,0)
MU HOS NQF 0376^76^77
"DATA",1130580001.101,37,1)
Incidence of potentially preventable VTE
"DATA",1130580001.101,37,5)
Incidence of potentially preventable VTE
"DATA",1130580001.101,37,6,0)
^^4^4^3110430^
"DATA",1130580001.101,37,6,1,0)
This measure assesses the number of patients diagnosed with confirmed VTE 
"DATA",1130580001.101,37,6,2,0)
during hospitalization (not present on arrival) who did not receive VTE 
"DATA",1130580001.101,37,6,3,0)
prophylaxis between hospital admission and the day before the VTE
"DATA",1130580001.101,37,6,4,0)
diagnostic testing order date.
"DATA",1130580001.101,37,7)
NQF0376
"DATA",1130580001.101,38,0)
12
"DATA",1130580001.101,39,0)
MU EP NQF 0421^156^152
"DATA",1130580001.101,39,1)
NQF0421 Adult Weight Screening and Follow-Up
"DATA",1130580001.101,39,5)
NQF0421 Adult Weight Screening and Follow-Up
"DATA",1130580001.101,39,6,0)
^1130580001.111^6^6^3110628^^^^
"DATA",1130580001.101,39,6,1,0)
Percentage of patients aged 18 
"DATA",1130580001.101,39,6,2,0)
years and older with a calculated BMI in the past 
"DATA",1130580001.101,39,6,3,0)
six months or during the current visit documented in 
"DATA",1130580001.101,39,6,4,0)
the medical record AND if the most recent BMI is 
"DATA",1130580001.101,39,6,5,0)
outside parameters, a follow-up plan is 
"DATA",1130580001.101,39,6,6,0)
documented.
"DATA",1130580001.101,39,7)
NQF0421
"DATA",1130580001.101,40,0)
MU EP NQF 0013^99^40
"DATA",1130580001.101,40,1)
NQF0013 Hypertension: Blood Pressure Measurement
"DATA",1130580001.101,40,5)
NQF0013 Hypertension: Blood Pressure Measurement
"DATA",1130580001.101,40,6,0)
^1130580001.111^4^4^3110628^^
"DATA",1130580001.101,40,6,1,0)
Percentage of patient visits for patients  
"DATA",1130580001.101,40,6,2,0)
aged 18 years and older with a diagnosis of hypertension 
"DATA",1130580001.101,40,6,3,0)
who have been seen for at least 2 office visits, with blood 
"DATA",1130580001.101,40,6,4,0)
pressure (BP) recorded
"DATA",1130580001.101,40,7)
NQF0013
"DATA",1130580001.101,41,0)
MU EP NQF 0028A^102^100
"DATA",1130580001.101,41,1)
NQF0028A Preventive Care and Screening  Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention 
"DATA",1130580001.101,41,5)
NQF0028A Tobacco Use Assessment
"DATA",1130580001.101,41,6,0)
^1130580001.111^7^7^3110625^^^
"DATA",1130580001.101,41,6,1,0)
 Percentage of patients aged 18 years and  
"DATA",1130580001.101,41,6,2,0)
older who have been seen for at least 2 office visits who 
"DATA",1130580001.101,41,6,3,0)
were queried about tobacco use one or more times within 
"DATA",1130580001.101,41,6,4,0)
24 months  b. Percentage of patients aged 18 years and 
"DATA",1130580001.101,41,6,5,0)
older  identified as tobacco users within the past 24 
"DATA",1130580001.101,41,6,6,0)
months and have been seen for at least 2 office visits, 
"DATA",1130580001.101,41,6,7,0)
who received cessation intervention.
"DATA",1130580001.101,41,7)
NQF0028A
"DATA",1130580001.101,42,0)
MU EP NQF 0041^144^132
"DATA",1130580001.101,42,1)
Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years Old 
"DATA",1130580001.101,42,5)
NQF0041 Influenza Immunization 50 years and older
"DATA",1130580001.101,42,6,0)
^^4^4^3110430^
"DATA",1130580001.101,42,6,1,0)
Percentage of patients aged 50 years 
"DATA",1130580001.101,42,6,2,0)
and older who received an influenza immunization 
"DATA",1130580001.101,42,6,3,0)
during the flu season (September through 
"DATA",1130580001.101,42,6,4,0)
February). 
"DATA",1130580001.101,42,7)
NQF0041
"DATA",1130580001.101,43,0)
MU EP NQF 0024^42^41
"DATA",1130580001.101,43,1)
NQF0024 Weight Assessment and Counseling for Children and Adolescents
"DATA",1130580001.101,43,5)
NQF0024 Weight Assessment and Counseling for Children and Adolescents 
"DATA",1130580001.101,43,6,0)
^^6^6^3110430^
"DATA",1130580001.101,43,6,1,0)
Percentage of patients 2 -17 years of age 
"DATA",1130580001.101,43,6,2,0)
who had an outpatient visit with a Primary Care Physician 
"DATA",1130580001.101,43,6,3,0)
(PCP) or OB/GYN and who had evidence of BMI 
"DATA",1130580001.101,43,6,4,0)
percentile documentation, counseling for nutrition and 
"DATA",1130580001.101,43,6,5,0)
counseling for physical activity during the measurement 
"DATA",1130580001.101,43,6,6,0)
year.
"DATA",1130580001.101,43,7)
NQF0024
"DATA",1130580001.101,44,0)
MU EP NQF 0038
"DATA",1130580001.101,44,1)
Childhood Immunization Status
"DATA",1130580001.101,44,5)
Childhood Immunization Status
"DATA",1130580001.101,44,6,0)
^^14^14^3110430^
"DATA",1130580001.101,44,6,1,0)
Percentage of children 2 years of age who 
"DATA",1130580001.101,44,6,2,0)
had four diphtheria, tetanus and acellular  pertussis 
"DATA",1130580001.101,44,6,3,0)
(DTaP); three polio(IPV), one measles, ,mumps and 
"DATA",1130580001.101,44,6,4,0)
rubella (MMR); two H influenza type B (HiB); three 
"DATA",1130580001.101,44,6,5,0)
Percentage of children 2 years of age who 
"DATA",1130580001.101,44,6,6,0)
had four diphtheria, tetanus and acellular  pertussis 
"DATA",1130580001.101,44,6,7,0)
(DTaP); three polio(IPV), one measles, ,mumps and 
"DATA",1130580001.101,44,6,8,0)
rubella (MMR); two H influenza type B (HiB); three 
"DATA",1130580001.101,44,6,9,0)
hepatitis B (Hep B); one chicken pox (VZV); four 
"DATA",1130580001.101,44,6,10,0)
pneumococcal conjugate (PCV); two hepatitis A (Hep A); 
"DATA",1130580001.101,44,6,11,0)
two or three rotavirus (RV); and two influenza (flu) 
"DATA",1130580001.101,44,6,12,0)
vaccines by their second birthday. The measure 
"DATA",1130580001.101,44,6,13,0)
calculates a rate for each vaccine and nine separate 
"DATA",1130580001.101,44,6,14,0)
combination rates.
"DATA",1130580001.101,44,7)
NQF0038
"DATA",1130580001.101,45,0)
MU EP NQF 0059^146^145
"DATA",1130580001.101,45,1)
Diabetes: Hemoglobin A1c Poor Contro
"DATA",1130580001.101,45,5)
Diabetes: NQF0059 Hemoglobin A1c Poor Control
"DATA",1130580001.101,45,6,0)
^^2^2^3110430^
"DATA",1130580001.101,45,6,1,0)
Percentage of patients 18 - 75 years of age with diabetes (type 1 
"DATA",1130580001.101,45,6,2,0)
or type 2) who had hemoglobin A1c > 9.0%.
"DATA",1130580001.101,45,7)
NQF0059
"DATA",1130580001.101,46,0)
MU EP NQF 0064^139^145
"DATA",1130580001.101,46,1)
Diabetes: Low Density Lipoprotein (LDL) Management and Control  
"DATA",1130580001.101,46,5)
NQF0064 Diabetes: Low Density Lipoprotein (LDL) Management and Control  
"DATA",1130580001.101,46,6,0)
^^3^3^3110430^
"DATA",1130580001.101,46,6,1,0)
Percentage of patients 18-75 years of age with diabetes (type 1 
"DATA",1130580001.101,46,6,2,0)
or type 2) who had LDL-C < 100 mg/dL).Percentage of patients 18-75 years 
"DATA",1130580001.101,46,6,3,0)
of age with diabetes (type 1 or type 2) who had LDL-C < 100 mg/dL).
"DATA",1130580001.101,46,7)
NQF0064
"DATA",1130580001.101,47,0)
MU EP NQF 0061^147^145
"DATA",1130580001.101,47,1)
Blood Pressure Management
"DATA",1130580001.101,47,5)
NQF0061 Diabetes: Blood Pressure Management
"DATA",1130580001.101,47,6,0)
^^2^2^3110430^
"DATA",1130580001.101,47,6,1,0)
Percentage of patients 18 - 75 years of age with 
"DATA",1130580001.101,47,6,2,0)
diabetes (type 1 or type 2) who had blood pressure <140/90 mmHg.
"DATA",1130580001.101,47,7)
NQF0061
"DATA",1130580001.101,48,0)
MU EP NQF 0081
"DATA",1130580001.101,48,1)
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) 
"DATA",1130580001.101,48,5)
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) 
"DATA",1130580001.101,48,6,0)
^^3^3^3110430^
"DATA",1130580001.101,48,6,1,0)
Percentage of patients aged 18 years and older with a 
"DATA",1130580001.101,48,6,2,0)
diagnosis of heart failure and LVSD (LVEF < 40%) who were 
"DATA",1130580001.101,48,6,3,0)
prescribed ACE inhibitor or ARB therapy
"DATA",1130580001.101,48,7)
NQF0081
"DATA",1130580001.101,49,0)
MU EP NQF 0070
"DATA",1130580001.101,49,1)
Pneumonia Vaccination Status for Older Adults
"DATA",1130580001.101,49,5)
Pneumonia Vaccination Status for Older Adults
"DATA",1130580001.101,49,6,0)
^^2^2^3110430^
"DATA",1130580001.101,49,6,1,0)
Percentage of patients 65 years of age and older who have ever 
"DATA",1130580001.101,49,6,2,0)
received a pneumococcal vaccine.
"DATA",1130580001.101,49,7)
NQF0070
"DATA",1130580001.101,50,0)
MU EP NQF 0031
"DATA",1130580001.101,50,1)
Breast Cancer Screening
"DATA",1130580001.101,50,5)
Breast Cancer Screening
"DATA",1130580001.101,50,6,0)
^^2^2^3110430^
"DATA",1130580001.101,50,6,1,0)
Percentage of women 40-69 years of age who had a 
"DATA",1130580001.101,50,6,2,0)
mammogram to screen for breast cancer
"DATA",1130580001.101,50,7)
NQF0031
"DATA",1130580001.101,51,0)
MU EP NQF 0034
"DATA",1130580001.101,51,1)
Colorectal Cancer Screening
"DATA",1130580001.101,51,5)
Colorectal Cancer Screening
"DATA",1130580001.101,51,6,0)
^^2^2^3110430^
"DATA",1130580001.101,51,6,1,0)
Percentage of adults 50-75 years of age who had appropriate screening for
"DATA",1130580001.101,51,6,2,0)
colorectal cancer.
"DATA",1130580001.101,51,7)
NQF0034
"DATA",1130580001.101,52,0)
MU EP NQF 0067
"DATA",1130580001.101,52,1)
Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD 
"DATA",1130580001.101,52,5)
Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD 
"DATA",1130580001.101,52,6,0)
^^2^2^3110430^
"DATA",1130580001.101,52,6,1,0)
Percentage of patients aged 18 years  and older with a 
"DATA",1130580001.101,52,6,2,0)
diagnosis of CAD who were prescribed oral antiplatelet therapy.
"DATA",1130580001.101,52,7)
NQF0067
"DATA",1130580001.101,53,0)
MU EP NQF 0083
"DATA",1130580001.101,53,1)
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) 
"DATA",1130580001.101,53,5)
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
"DATA",1130580001.101,53,6,0)
^^3^3^3110430^
"DATA",1130580001.101,53,6,1,0)
Percentage of patients aged 18 years and older with a 
"DATA",1130580001.101,53,6,2,0)
diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were 
"DATA",1130580001.101,53,6,3,0)
prescribed beta-blocker therapy
"DATA",1130580001.101,53,7)
NQF0083
"DATA",1130580001.101,54,0)
MU EP NQF 0105
"DATA",1130580001.101,54,1)
Anti-depressant medication management:  (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment  
"DATA",1130580001.101,54,5)
Anti-depressant medication management:  (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment  
"DATA",1130580001.101,54,6,0)
^^4^4^3110430^
"DATA",1130580001.101,54,6,1,0)
The percentage of patients 18 years of age and older 
"DATA",1130580001.101,54,6,2,0)
who were diagnosed with a new episode of major depression, treated 
"DATA",1130580001.101,54,6,3,0)
with antidepressant medication, and who remained on an 
"DATA",1130580001.101,54,6,4,0)
antidepressant medication treatment.
"DATA",1130580001.101,54,7)
NQF0105
"DATA",1130580001.101,55,0)
MU EP NQF 0086
"DATA",1130580001.101,55,1)
Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
"DATA",1130580001.101,55,5)
Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
"DATA",1130580001.101,55,6,0)
^^4^4^3110430^
"DATA",1130580001.101,55,6,1,0)
Percentage of patients aged 18 years and older with a 
"DATA",1130580001.101,55,6,2,0)
diagnosis of POAG who have been seen for at least two office visits 
"DATA",1130580001.101,55,6,3,0)
who have an optic nerve head evaluation during one or more office 
"DATA",1130580001.101,55,6,4,0)
visits within 12 months.
"DATA",1130580001.101,55,7)
NQF0086
"DATA",1130580001.101,56,0)
MU EP NQF 0088
"DATA",1130580001.101,56,1)
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy 
"DATA",1130580001.101,56,5)
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy 
"DATA",1130580001.101,56,6,0)
^^5^5^3110430^
"DATA",1130580001.101,56,6,1,0)
Percentage of patients aged 18 years and older with a 
"DATA",1130580001.101,56,6,2,0)
diagnosis of diabetic retinopathy who had a dilated macular or fundus 
"DATA",1130580001.101,56,6,3,0)
exam performed which included documentation of the level of severity 
"DATA",1130580001.101,56,6,4,0)
of  retinopathy and the presence or absence of macular edema during 
"DATA",1130580001.101,56,6,5,0)
one or more office visits within 12 months.
"DATA",1130580001.101,56,7)
NQF0088
"DATA",1130580001.101,57,0)
MU EP NQF 0089
"DATA",1130580001.101,57,1)
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care 
"DATA",1130580001.101,57,5)
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care 
"DATA",1130580001.101,57,6,0)
^^6^6^3110430^
"DATA",1130580001.101,57,6,1,0)
Percentage of patients aged 18 years and older with a 
"DATA",1130580001.101,57,6,2,0)
diagnosis of diabetic retinopathy who had a dilated macular or fundus 
"DATA",1130580001.101,57,6,3,0)
exam performed with documented communication to the physician who 
"DATA",1130580001.101,57,6,4,0)
manages the ongoing care of the patient with diabetes mellitus 
"DATA",1130580001.101,57,6,5,0)
regarding the findings of the macular or fundus exam at least once 
"DATA",1130580001.101,57,6,6,0)
within 12 months.
"DATA",1130580001.101,57,7)
NQF0089
"DATA",1130580001.101,58,0)
MU EP NQF 0047
"DATA",1130580001.101,58,1)
Asthma Pharmacologic Therapy
"DATA",1130580001.101,58,5)
Asthma Pharmacologic Therapy
"DATA",1130580001.101,58,6,0)
^1130580001.111^4^4^3110430^^
"DATA",1130580001.101,58,6,1,0)
Percentage of patients aged 5 through 40 years with a 
"DATA",1130580001.101,58,6,2,0)
diagnosis of mild, moderate, or severe persistent asthma who were 
"DATA",1130580001.101,58,6,3,0)
prescribed either the preferred long-term control medication (inhaled 
"DATA",1130580001.101,58,6,4,0)
corticosteroid) or an acceptable alternative treatment
"DATA",1130580001.101,58,7)
NQF0047
"DATA",1130580001.101,59,0)
MU EP NQF 0001
"DATA",1130580001.101,59,1)
Asthma Assessment
"DATA",1130580001.101,59,5)
Asthma Assessment 
"DATA",1130580001.101,59,6,0)
^^5^5^3110430^
"DATA",1130580001.101,59,6,1,0)
Percentage of patients aged 5 through 40 years with a 
"DATA",1130580001.101,59,6,2,0)
diagnosis of asthma and who have been seen for at least 2 office 
"DATA",1130580001.101,59,6,3,0)
visits, who were evaluated during at least one office visit within 12 
"DATA",1130580001.101,59,6,4,0)
months for the frequency (numeric) of daytime and nocturnal asthma 
"DATA",1130580001.101,59,6,5,0)
symptoms.
"DATA",1130580001.101,59,7)
NQF0001
"DATA",1130580001.101,60,0)
MU EP NQF 0002
"DATA",1130580001.101,60,1)
Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breat Cancer 
"DATA",1130580001.101,60,5)
Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer 
"DATA",1130580001.101,60,6,0)
^^4^4^3110430^
"DATA",1130580001.101,60,6,1,0)
Percentage of female patients aged 18 years and older 
"DATA",1130580001.101,60,6,2,0)
with Stage IC through IIIC, ER or PR positive breast cancer who were 
"DATA",1130580001.101,60,6,3,0)
prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month 
"DATA",1130580001.101,60,6,4,0)
reporting period.
"DATA",1130580001.101,60,7)
NQF0002
"DATA",1130580001.101,61,0)
MU EP NQF 0385
"DATA",1130580001.101,61,1)
Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients 
"DATA",1130580001.101,61,5)
Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients 
"DATA",1130580001.101,61,6,0)
^^4^4^3110430^
"DATA",1130580001.101,61,6,1,0)
Percentage of patients aged 18 years and older with 
"DATA",1130580001.101,61,6,2,0)
Stage IIIA through IIIC colon cancer who are referred for adjuvant 
"DATA",1130580001.101,61,6,3,0)
chemotherapy, prescribed adjuvant chemotherapy, or have previously 
"DATA",1130580001.101,61,6,4,0)
received adjuvant chemotherapy within the 12-month reporting period
"DATA",1130580001.101,61,7)
NQF0385
"DATA",1130580001.101,62,0)
MU EP NQF 0389
"DATA",1130580001.101,62,1)
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients 
"DATA",1130580001.101,62,5)
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients 
"DATA",1130580001.101,62,6,0)
^^5^5^3110430^
"DATA",1130580001.101,62,6,1,0)
Percentage of patients, regardless of age, with a diagnosis of 
"DATA",1130580001.101,62,6,2,0)
prostate cancer at low risk of recurrence receiving interstitial prostate 
"DATA",1130580001.101,62,6,3,0)
brachytherapy, OR external beam radiotherapy to the prostate, OR radical 
"DATA",1130580001.101,62,6,4,0)
prostatectomy, OR cryotherapy who did not have a bone scan performed at 
"DATA",1130580001.101,62,6,5,0)
any time since diagnosis of prostate cancer.
"DATA",1130580001.101,62,7)
NQF0389
"DATA",1130580001.101,63,0)
MU EP NQF 0027
"DATA",1130580001.101,63,1)
Smoking Smokers and Tobacco Users to Quit,b. Discussing Smoking and Tobacco use Cessation Medications, c. Discussing Smoking and Tobacco use Cessation Strategies and Tobacco Use Cessation, Medical assistance: a. Advising 
"DATA",1130580001.101,63,5)
Smoking and Tobacco Use Cessation
"DATA",1130580001.101,63,6,0)
^^5^5^3110430^
"DATA",1130580001.101,63,6,1,0)
Percentage of patients 18 years of age and older who were 
"DATA",1130580001.101,63,6,2,0)
current smokers or tobacco users, who were seen by a practitioner during 
"DATA",1130580001.101,63,6,3,0)
the measurement year and who received advice to quit smoking or  tobacco
"DATA",1130580001.101,63,6,4,0)
use or whose practitioner recommended or discussed smoking or tobacco use
"DATA",1130580001.101,63,6,5,0)
cessation medications, methods or strategies
"DATA",1130580001.101,63,7)
NQF0027
"DATA",1130580001.101,64,0)
MU EP NQF 0055
"DATA",1130580001.101,64,1)
Diabetes: Eye Exam
"DATA",1130580001.101,64,5)
Diabetes: Eye Exam
"DATA",1130580001.101,64,6,0)
^^3^3^3110430^
"DATA",1130580001.101,64,6,1,0)
Percentage of patients 18 -75 years of age with diabetes (type 1 
"DATA",1130580001.101,64,6,2,0)
or type 2) who had a retinal or dilated eye exam or a negative retinal 
"DATA",1130580001.101,64,6,3,0)
exam (no evidence of retinopathy) by an eye care professional
"DATA",1130580001.101,64,7)
NQF0055
"DATA",1130580001.101,65,0)
MU EP NQF 0062
"DATA",1130580001.101,65,1)
Diabetes: Urine Screening
"DATA",1130580001.101,65,5)
Diabetes: Urine Screening
"DATA",1130580001.101,65,6,0)
^^3^3^3110430^
"DATA",1130580001.101,65,6,1,0)
Percentage of patients 18 - 75 years of age with diabetes (type 1 
"DATA",1130580001.101,65,6,2,0)
or type 2) who had a nephropathy screening test or evidence of 
"DATA",1130580001.101,65,6,3,0)
nephropathy.
"DATA",1130580001.101,65,7)
NQF0062
"DATA",1130580001.101,66,0)
MU EP NQF 0056
"DATA",1130580001.101,66,1)
Diabetes:  Foot Exam
"DATA",1130580001.101,66,5)
Diabetes:  Foot Exam
"DATA",1130580001.101,66,6,0)
^^3^3^3110430^
"DATA",1130580001.101,66,6,1,0)
The percentage of patients aged 18 - 75 years with diabetes 
"DATA",1130580001.101,66,6,2,0)
(type 1 or type 2) who had a foot exam (visual inspection, sensory exam 
"DATA",1130580001.101,66,6,3,0)
with monofilament, or pulse exam).
"DATA",1130580001.101,66,7)
NQF0056
"DATA",1130580001.101,67,0)
MU EP NQF 0074
"DATA",1130580001.101,67,1)
Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
"DATA",1130580001.101,67,5)
Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
"DATA",1130580001.101,67,6,0)
^^3^3^3110430^
"DATA",1130580001.101,67,6,1,0)
Percentage of patients aged 18 years and older with a 
"DATA",1130580001.101,67,6,2,0)
diagnosis of CAD who were prescribed a lipid-lowering therapy (based 
"DATA",1130580001.101,67,6,3,0)
on current ACC/AHA guidelines).
"DATA",1130580001.101,67,7)
NQF0074
"DATA",1130580001.101,68,0)
MU EP NQF 0084
"DATA",1130580001.101,68,1)
Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
"DATA",1130580001.101,68,5)
Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
"DATA",1130580001.101,68,6,0)
^^3^3^3110430^
"DATA",1130580001.101,68,6,1,0)
Percentage of all patients aged 18 years and older with a 
"DATA",1130580001.101,68,6,2,0)
diagnosis of heart failure and paroxysmal or chronic atrial fibrillation 
"DATA",1130580001.101,68,6,3,0)
who were prescribed warfarin therapy.
"DATA",1130580001.101,68,7)
NQF0084
"DATA",1130580001.101,69,0)
MU EP NQF 0073
"DATA",1130580001.101,69,1)
Ischemic Vascular Disease (IVD):  Blood Pressure Management
"DATA",1130580001.101,69,5)
Ischemic Vascular Disease (IVD):  Blood Pressure Management
"DATA",1130580001.101,69,6,0)
^^11^11^3110430^
"DATA",1130580001.101,69,6,1,0)
Percentage of patients 18 years of age and older who 
"DATA",1130580001.101,69,6,2,0)
were discharged alive for acute myocardial infarction (AMI), coronary 
"DATA",1130580001.101,69,6,3,0)
artery bypass graft (CABG) or percutaneous transluminal coronary 
"DATA",1130580001.101,69,6,4,0)
Percentage of patients 18 years of age and older who 
"DATA",1130580001.101,69,6,5,0)
were discharged alive for acute myocardial infarction (AMI), coronary 
"DATA",1130580001.101,69,6,6,0)
artery bypass graft (CABG) or percutaneous transluminal coronary 
"DATA",1130580001.101,69,6,7,0)
angioplasty (PTCA) from January 1- November 1 of the year prior to 
"DATA",1130580001.101,69,6,8,0)
the measurement year, or who had a diagnosis of ischemic vascular 
"DATA",1130580001.101,69,6,9,0)
disease (IVD) during the measurement year and the year prior to the 
"DATA",1130580001.101,69,6,10,0)
measurement year and whose recent blood pressure is in control 
"DATA",1130580001.101,69,6,11,0)
(<140/90 mmHg).
"DATA",1130580001.101,69,7)
NQF0073
"DATA",1130580001.101,70,0)
MU EP NQF 0068
"DATA",1130580001.101,70,1)
Ischemic Vascular Disease (IVD):  Use of Aspirin or Another Antithrombotic 
"DATA",1130580001.101,70,5)
 Ischemic Vascular Disease (IVD):  Use of Aspirin or Another Antithrombotic 
"DATA",1130580001.101,70,6,0)
^^8^8^3110430^
"DATA",1130580001.101,70,6,1,0)
 Percentage of patients 18 years of age and older who were 
"DATA",1130580001.101,70,6,2,0)
discharged alive for acute myocardial infarction (AMI), coronary artery 
"DATA",1130580001.101,70,6,3,0)
bypass graft (CABG) or percutaneous transluminal coronary 
"DATA",1130580001.101,70,6,4,0)
angioplasty (PTCA) from January 1-November 1 of the year prior to the 
"DATA",1130580001.101,70,6,5,0)
measurement year, or who had a diagnosis of ischemic vascular 
"DATA",1130580001.101,70,6,6,0)
disease (IVD) during the measurement year and the year prior to the 
"DATA",1130580001.101,70,6,7,0)
measurement year and who had documentation of use of aspirin or 
"DATA",1130580001.101,70,6,8,0)
another antithrombotic during the measurement year
"DATA",1130580001.101,70,7)
NQF0068
"DATA",1130580001.101,71,0)
MU EP NQF 0004
"DATA",1130580001.101,71,1)
 Initiation and Engagement of Alcohol and Other Drug  Dependence Treatment:(a)Initiation,(b)Engagement 
"DATA",1130580001.101,71,5)
Initiation and Engagement of Alcohol and Other Drug  Dependence Treatment:(a) Initiation,(b) Engagement 
"DATA",1130580001.101,71,6,0)
^^6^6^3110430^
"DATA",1130580001.101,71,6,1,0)
The percentage of adolescent and adult patients with a new 
"DATA",1130580001.101,71,6,2,0)
episode of alcohol and other drug (AOD) dependence who initiate treatment 
"DATA",1130580001.101,71,6,3,0)
through an inpatient AOD admission, outpatient visit, intensive 
"DATA",1130580001.101,71,6,4,0)
outpatient encounter or partial hospitalization within 14 days of the
"DATA",1130580001.101,71,6,5,0)
diagnosis and who initiated treatment and who had two or more additional
"DATA",1130580001.101,71,6,6,0)
services with an AOD diagnosis within 30 days of the initiation visit.
"DATA",1130580001.101,71,7)
NQF0004
"DATA",1130580001.101,72,0)
MU EP NQF 0012
"DATA",1130580001.101,72,1)
Prenatal Care:  Screening for Human Immunodeficiency Virus (HIV)
"DATA",1130580001.101,72,5)
Prenatal Care:  Screening for Human Immunodeficiency Virus (HIV)
"DATA",1130580001.101,72,6,0)
^^3^3^3110430^
"DATA",1130580001.101,72,6,1,0)
Percentage of patients, regardless of age, who gave birth during 
"DATA",1130580001.101,72,6,2,0)
a 12-month period who were screened for HIV infection during the first or 
"DATA",1130580001.101,72,6,3,0)
second prenatal care visit.
"DATA",1130580001.101,72,7)
NQF0012
"DATA",1130580001.101,73,0)
MU EP NQF 0014
"DATA",1130580001.101,73,1)
Prenatal Care:  Anti-D Immune Globulin
"DATA",1130580001.101,73,5)
Prenatal Care:  Anti-D Immune Globulin 
"DATA",1130580001.101,73,6,0)
^^3^3^3110430^
"DATA",1130580001.101,73,6,1,0)
Percentage of D (Rh) negative, unsensitized patients, regardless 
"DATA",1130580001.101,73,6,2,0)
of age, who gave birth during a 12-month period who received anti-D 
"DATA",1130580001.101,73,6,3,0)
immune globulin at 26-30 weeks gestation.
"DATA",1130580001.101,73,7)
NQD0014
"DATA",1130580001.101,74,0)
MU EP NQF 0018
"DATA",1130580001.101,74,1)
Controlling High Blood Pressure
"DATA",1130580001.101,74,5)
Controlling High Blood Pressure
"DATA",1130580001.101,74,6,0)
^^3^3^3110430^
"DATA",1130580001.101,74,6,1,0)
The percentage of patients 18-85 years of age who had a 
"DATA",1130580001.101,74,6,2,0)
diagnosis of hypertension and whose BP was adequately controlled during 
"DATA",1130580001.101,74,6,3,0)
the measurement year 
"DATA",1130580001.101,74,7)
NQF0018
"DATA",1130580001.101,75,0)
MU EP NQF 0032
"DATA",1130580001.101,75,1)
Cervical Cancer Screening
"DATA",1130580001.101,75,5)
Cervical Cancer Screening
"DATA",1130580001.101,75,6,0)
^^2^2^3110430^
"DATA",1130580001.101,75,6,1,0)
Percentage of women 21-64 years of age, who received one or 
"DATA",1130580001.101,75,6,2,0)
more Pap tests to screen for cervical cancer
"DATA",1130580001.101,75,7)
NQF0032
"DATA",1130580001.101,76,0)
MU EP NQF 0033
"DATA",1130580001.101,76,1)
Chlamydia Screening for Women
"DATA",1130580001.101,76,5)
Chlamydia Screening for Women
"DATA",1130580001.101,76,6,0)
^^3^3^3110430^
"DATA",1130580001.101,76,6,1,0)
Percentage of women 15- 24 years of age who were identified as sexually
"DATA",1130580001.101,76,6,2,0)
active and who had at least one test for chlamydia during the measurement
"DATA",1130580001.101,76,6,3,0)
year.
"DATA",1130580001.101,76,7)
NQF0033
"DATA",1130580001.101,77,0)
MU EP NQF 0036
"DATA",1130580001.101,77,1)
Use of Appropriate Medications for Asthma
"DATA",1130580001.101,77,5)
Use of Appropriate Medications for Asthma
"DATA",1130580001.101,77,6,0)
^^4^4^3110430^
"DATA",1130580001.101,77,6,1,0)
Percentage of patients 5 - 50 years of age who were identified as having
"DATA",1130580001.101,77,6,2,0)
persistent asthma and were appropriately prescribed medication during the
"DATA",1130580001.101,77,6,3,0)
measurement year. Report three age stratifications (5-11 years, 12-50
"DATA",1130580001.101,77,6,4,0)
years, and total). 
"DATA",1130580001.101,77,7)
NQF0036
"DATA",1130580001.101,78,0)
MU EP NQF 0052
"DATA",1130580001.101,78,1)
Low Back Pain: Use of Imaging Studies
"DATA",1130580001.101,78,5)
Low Back Pain: Use of Imaging Studies
"DATA",1130580001.101,78,6,0)
^1130580001.111^3^3^3110430^^
"DATA",1130580001.101,78,6,1,0)
Percentage of patients with a primary diagnosis of low back pain 
"DATA",1130580001.101,78,6,2,0)
who did not have an imaging study (plain x-ray, MRI, CT scan) within 28 
"DATA",1130580001.101,78,6,3,0)
days of diagnosis.
"DATA",1130580001.101,78,7)
NQF0052
"DATA",1130580001.101,79,0)
MU EP NQF 0075
"DATA",1130580001.101,79,1)
Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control 
"DATA",1130580001.101,79,5)
Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control 
"DATA",1130580001.101,79,6,0)
^^7^7^3110430^
"DATA",1130580001.101,79,6,1,0)
Percentage of patients 18 years of age and older who were discharged alive
"DATA",1130580001.101,79,6,2,0)
for acute myocardial infarction (AMI), coronary artery bypass graft (CABG)
"DATA",1130580001.101,79,6,3,0)
or percutaneous transluminal angioplasty (PTCA) from January 1-November1
"DATA",1130580001.101,79,6,4,0)
of the year prior to the measurement year, or who had a diagnosis of
"DATA",1130580001.101,79,6,5,0)
ischemic vascular disease (IVD) during the measurement year and the year
"DATA",1130580001.101,79,6,6,0)
prior to the measurement year and who had a complete lipid profile
"DATA",1130580001.101,79,6,7,0)
performed during the measurement year and whose LDL-C<100 mg/dL
"DATA",1130580001.101,79,7)
NQF0075
"DATA",1130580001.101,80,0)
MU EP NQF 0575
"DATA",1130580001.101,80,1)
Diabetes:  Hemoglobin A1c Control (<8.0%)
"DATA",1130580001.101,80,5)
Diabetes:  Hemoglobin A1c Control (<8.0%)
"DATA",1130580001.101,80,6,0)
^^2^2^3110430^
"DATA",1130580001.101,80,6,1,0)
The percentage of patients 18-75 years of age with diabetes 
"DATA",1130580001.101,80,6,2,0)
(type 1 or type 2) who had hemoglobin A1c <8.0%
"DATA",1130580001.101,80,7)
NQF0575
"DATA",1130580001.101,81,0)
MU EP NQF 0028B^104^103
"DATA",1130580001.101,81,1)
NQF0028B Preventive Care and Screening  Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention 
"DATA",1130580001.101,81,5)
NQF0028B Tobacco Use Assessment and Cessation Intervention
"DATA",1130580001.101,81,6,0)
^1130580001.111^7^7^3110625^^^^
"DATA",1130580001.101,81,6,1,0)
 Percentage of patients aged 18 years and  
"DATA",1130580001.101,81,6,2,0)
older who have been seen for at least 2 office visits who 
"DATA",1130580001.101,81,6,3,0)
were queried about tobacco use one or more times within 
"DATA",1130580001.101,81,6,4,0)
24 months  b. Percentage of patients aged 18 years and 
"DATA",1130580001.101,81,6,5,0)
older  identified as tobacco users within the past 24 
"DATA",1130580001.101,81,6,6,0)
months and have been seen for at least 2 office visits, 
"DATA",1130580001.101,81,6,7,0)
who received cessation intervention.
"DATA",1130580001.101,81,7)
NQF0028B
"DATA",1130580001.101,82,0)
MU EP 0028B
"DATA",1130580001.101,83,0)
NQF0038 NUM1 DPT^115^109
"DATA",1130580001.101,83,5)
NQF0038 NUM1 DPT
"DATA",1130580001.101,83,7)
NQF0038 NUM1 DPT
"DATA",1130580001.101,84,0)
NQF0038 NUM2 IPV^123^109
"DATA",1130580001.101,84,5)
NQF0038 NUM2 IPV
"DATA",1130580001.101,84,7)
NQF0038 NUM2 IPV
"DATA",1130580001.101,85,0)
NQF0038 NUM3 MMR^114^109
"DATA",1130580001.101,85,5)
NQF0038 NUM3 MMR
"DATA",1130580001.101,85,7)
NQF0038 NUM3 MMR
"DATA",1130580001.101,86,0)
NQF0038 NUM4 HiB^116^109
"DATA",1130580001.101,86,5)
NQF0038 NUM4 HiB
"DATA",1130580001.101,86,7)
NQF0038 NUM4 HiB
"DATA",1130580001.101,87,0)
NQF0038 NUM5 HEP B^117^109
"DATA",1130580001.101,87,5)
NQF0038 NUM5 HEP B
"DATA",1130580001.101,87,7)
NQF0038 NUM5 HEP B
"DATA",1130580001.101,88,0)
NQF0038 NUM6 VZV^118^109
"DATA",1130580001.101,88,5)
NQF0038 NUM6 VZV
"DATA",1130580001.101,88,7)
NQF0038 NUM6 VZV
"DATA",1130580001.101,89,0)
NQF0038 NUM7 PCV^119^109
"DATA",1130580001.101,89,5)
NQF0038 NUM7 PCV
"DATA",1130580001.101,89,7)
NQF0038 NUM7 PCV
"DATA",1130580001.101,90,0)
NQF0038 NUM8 HEP A^120^109
"DATA",1130580001.101,90,5)
NQF0038 NUM8 HEP A
"DATA",1130580001.101,90,7)
NQF0038 NUM8 HEP A
"DATA",1130580001.101,91,0)
NQF0038 NUM9^121^109
"DATA",1130580001.101,91,5)
NQF0038 NUM9
"DATA",1130580001.101,91,7)
NQF0038 NUM9
"DATA",1130580001.101,92,0)
NQF0038 NUM10^122^109
"DATA",1130580001.101,92,5)
NQF0038 NUM10
"DATA",1130580001.101,92,7)
NQF0038 NUM10
"DATA",1130580001.101,93,0)
NQF0038 NUM11 COMBO5^124^109
"DATA",1130580001.101,93,5)
NQF0038 NUM11 COMBO5
"DATA",1130580001.101,93,7)
NQF0038 NUM11 COMBO5
"DATA",1130580001.101,94,0)
NQF0038 NUM12 COMBO6^125^109
"DATA",1130580001.101,94,5)
NQF0038 NUM12 COMBO6
"DATA",1130580001.101,94,7)
NQF0038 NUM12 COMBO6
"DATA",1130580001.101,95,0)
MU 2011 INP ADV DIRECTIVES
"DATA",1130580001.101,95,5)
Advance Directives
"DATA",1130580001.101,95,7)
^15^14^^17
"DATA",1130580001.101,96,0)
MU 2011 INP CPOE
"DATA",1130580001.101,96,5)
CPOE for Medications
"DATA",1130580001.101,96,7)
^10^30^^11
"DATA",1130580001.101,97,0)
MU 2011 INP MED RECON
"DATA",1130580001.101,97,5)
Medication Reconcilliation
"DATA",1130580001.101,97,7)
^19^21^^20
"DATA",1130580001.101,98,0)
MU 2011 INP PROBLEM LIST
"DATA",1130580001.101,98,5)
Problem List
"DATA",1130580001.101,98,7)
^27^30^^29
"DATA",1130580001.101,99,0)
MU 2011 INP VITAL SIGNS
"DATA",1130580001.101,99,5)
Record Vital Signs
"DATA",1130580001.101,99,7)
^16^30^^18
"DATA",1130580001.101,100,0)
MU 2011 INP SMOKING STATUS
"DATA",1130580001.101,100,5)
Smoking Status
"DATA",1130580001.101,100,7)
^12^30^^13
"DATA",1130580001.101,101,0)
MU 2011 INP MED LIST
"DATA",1130580001.101,101,5)
Active Medication List
"DATA",1130580001.101,101,7)
^26^30^^5
"DATA",1130580001.101,102,0)
MU 2011 INP ALLERGY LIST
"DATA",1130580001.101,102,5)
Medication Allergy List
"DATA",1130580001.101,102,7)
^24^30^^28
"DATA",1130580001.101,103,0)
MU 2011 INP DEMOGRAPHICS
"DATA",1130580001.101,103,5)
Record Demographics
"DATA",1130580001.101,103,7)
^25^30^^9
"FIA",1130580001.101)
C0Q QUALITY MEASURE
"FIA",1130580001.101,0)
^C0Q(101,
"FIA",1130580001.101,0,0)
1130580001.101I
"FIA",1130580001.101,0,1)
y^y^f^^n^^y^m^y
"FIA",1130580001.101,0,10)

"FIA",1130580001.101,0,11)

"FIA",1130580001.101,0,"RLRO")

"FIA",1130580001.101,1130580001.101)
0
"FIA",1130580001.101,1130580001.111)
0
"IX",1130580001.101,1130580001.101,"MU",0)
1130580001.101^MU^MEANINGFUL USE YEAR KEY^R^^F^IR^I^1130580001.101^^^^^LS
"IX",1130580001.101,1130580001.101,"MU",1)
S ^C0Q(101,"MU",$E(X,1,30),DA)=""
"IX",1130580001.101,1130580001.101,"MU",2)
K ^C0Q(101,"MU",$E(X,1,30),DA)
"IX",1130580001.101,1130580001.101,"MU",2.5)
K ^C0Q(101,"MU")
"IX",1130580001.101,1130580001.101,"MU",11.1,0)
^.114IA^1^1
"IX",1130580001.101,1130580001.101,"MU",11.1,1,0)
1^F^1130580001.101^.3^30^1^F
"MBREQ")
0
"QUES","XPF1",0)
Y
"QUES","XPF1","??")
^D REP^XPDH
"QUES","XPF1","A")
Shall I write over your |FLAG| File
"QUES","XPF1","B")
YES
"QUES","XPF1","M")
D XPF1^XPDIQ
"QUES","XPF2",0)
Y
"QUES","XPF2","??")
^D DTA^XPDH
"QUES","XPF2","A")
Want my data |FLAG| yours
"QUES","XPF2","B")
YES
"QUES","XPF2","M")
D XPF2^XPDIQ
"QUES","XPI1",0)
YO
"QUES","XPI1","??")
^D INHIBIT^XPDH
"QUES","XPI1","A")
Want KIDS to INHIBIT LOGONs during the install
"QUES","XPI1","B")
NO
"QUES","XPI1","M")
D XPI1^XPDIQ
"QUES","XPM1",0)
PO^VA(200,:EM
"QUES","XPM1","??")
^D MG^XPDH
"QUES","XPM1","A")
Enter the Coordinator for Mail Group '|FLAG|'
"QUES","XPM1","B")

"QUES","XPM1","M")
D XPM1^XPDIQ
"QUES","XPO1",0)
Y
"QUES","XPO1","??")
^D MENU^XPDH
"QUES","XPO1","A")
Want KIDS to Rebuild Menu Trees Upon Completion of Install
"QUES","XPO1","B")
NO
"QUES","XPO1","M")
D XPO1^XPDIQ
"QUES","XPZ1",0)
Y
"QUES","XPZ1","??")
^D OPT^XPDH
"QUES","XPZ1","A")
Want to DISABLE Scheduled Options, Menu Options, and Protocols
"QUES","XPZ1","B")
NO
"QUES","XPZ1","M")
D XPZ1^XPDIQ
"QUES","XPZ2",0)
Y
"QUES","XPZ2","??")
^D RTN^XPDH
"QUES","XPZ2","A")
Want to MOVE routines to other CPUs
"QUES","XPZ2","B")
NO
"QUES","XPZ2","M")
D XPZ2^XPDIQ
"SEC","^DD",1130580001.101,1130580001.101,3.1,9)

"SEC","^DIC",1130580001.101,1130580001.101,0,"AUDIT")
@
"SEC","^DIC",1130580001.101,1130580001.101,0,"DD")
@
"SEC","^DIC",1130580001.101,1130580001.101,0,"DEL")
@
"SEC","^DIC",1130580001.101,1130580001.101,0,"LAYGO")
@
"SEC","^DIC",1130580001.101,1130580001.101,0,"RD")
@
"SEC","^DIC",1130580001.101,1130580001.101,0,"WR")
@
"VER")
8.0^22.0
"^DD",1130580001.101,1130580001.101,0)
FIELD^^.3^15
"^DD",1130580001.101,1130580001.101,0,"DDA")
N
"^DD",1130580001.101,1130580001.101,0,"DT")
3111201
"^DD",1130580001.101,1130580001.101,0,"ID",.7)
W:$D(^(5)) "   ",$P(^(5),U,1)
"^DD",1130580001.101,1130580001.101,0,"IX","B",1130580001.101,.01)

"^DD",1130580001.101,1130580001.101,0,"NM","C0Q QUALITY MEASURE")

"^DD",1130580001.101,1130580001.101,0,"PT",1130580001.2011,.01)

"^DD",1130580001.101,1130580001.101,.01,0)
NAME^RF^^0;1^K:$L(X)>30!($L(X)<1)!'(X'?1P.E) X
"^DD",1130580001.101,1130580001.101,.01,.1)
MEASURE NAME
"^DD",1130580001.101,1130580001.101,.01,1,0)
^.1
"^DD",1130580001.101,1130580001.101,.01,1,1,0)
1130580001.101^B
"^DD",1130580001.101,1130580001.101,.01,1,1,1)
S ^C0Q(101,"B",$E(X,1,30),DA)=""
"^DD",1130580001.101,1130580001.101,.01,1,1,2)
K ^C0Q(101,"B",$E(X,1,30),DA)
"^DD",1130580001.101,1130580001.101,.01,3)
Answer must be 1-30 characters in length
"^DD",1130580001.101,1130580001.101,.01,"DT")
3101012
"^DD",1130580001.101,1130580001.101,.3,0)
MU YEAR KEY^F^^7;6^K:$L(X)>30!($L(X)<1) X
"^DD",1130580001.101,1130580001.101,.3,.1)
MEANINGFUL USE YEAR KEY
"^DD",1130580001.101,1130580001.101,.3,3)
Answer must be 1-30 characters in length.
"^DD",1130580001.101,1130580001.101,.3,"DT")
3111201
"^DD",1130580001.101,1130580001.101,.5,0)
TITLE^F^^1;1^K:$L(X)>240!($L(X)<3) X
"^DD",1130580001.101,1130580001.101,.5,.1)
MEASURE TITLE
"^DD",1130580001.101,1130580001.101,.5,3)
Answer must be 3-240 characters in length
"^DD",1130580001.101,1130580001.101,.5,"DT")
3110430
"^DD",1130580001.101,1130580001.101,.61,0)
VERY LONG DESCRIPTION^1130580001.111^^6;0
"^DD",1130580001.101,1130580001.101,.7,0)
DISPLAY NAME^F^^5;1^K:$L(X)>240!($L(X)<3) X
"^DD",1130580001.101,1130580001.101,.7,.1)
QRDA DISPLAY NAME
"^DD",1130580001.101,1130580001.101,.7,3)
Answer must be 3-240 characters in length
"^DD",1130580001.101,1130580001.101,.7,"DT")
3101012
"^DD",1130580001.101,1130580001.101,.8,0)
REPORTING NAME^F^^7;1^K:$L(X)>30!($L(X)<3) X
"^DD",1130580001.101,1130580001.101,.8,.1)
REPORTING MEASURE NAME
"^DD",1130580001.101,1130580001.101,.8,3)
Answer must be 3-30 characters in length
"^DD",1130580001.101,1130580001.101,.8,"DT")
3110615
"^DD",1130580001.101,1130580001.101,1,0)
NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
"^DD",1130580001.101,1130580001.101,1,.1)
MEASURE NUMERATOR PATIENT LIST
"^DD",1130580001.101,1130580001.101,1,"DT")
3101012
"^DD",1130580001.101,1130580001.101,1.1,0)
ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
"^DD",1130580001.101,1130580001.101,1.1,"DT")
3110805
"^DD",1130580001.101,1130580001.101,1.5,0)
NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
"^DD",1130580001.101,1130580001.101,1.5,.1)
LIST OF PATIENTS THAT DO NOT MEET THE REQUIREMENTS
"^DD",1130580001.101,1130580001.101,1.5,"DT")
3110809
"^DD",1130580001.101,1130580001.101,1.51,0)
ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
"^DD",1130580001.101,1130580001.101,1.51,.1)
NEGATIVE NUMERATOR LIST IN C0Q PATIENT LIST FILE
"^DD",1130580001.101,1130580001.101,1.51,"DT")
3110809
"^DD",1130580001.101,1130580001.101,2,0)
DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
"^DD",1130580001.101,1130580001.101,2,.1)
MEASURE DENOMINATOR PATIENT LIST
"^DD",1130580001.101,1130580001.101,2,"DT")
3101012
"^DD",1130580001.101,1130580001.101,2.1,0)
ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
"^DD",1130580001.101,1130580001.101,2.1,"DT")
3110805
"^DD",1130580001.101,1130580001.101,3,0)
QRDA TEMPLATE ROOT^F^^0;4^K:$L(X)>120!($L(X)<3) X
"^DD",1130580001.101,1130580001.101,3,.1)
MEASURE TEMPLATE ROOT FOR QRDA DOCUMENT
"^DD",1130580001.101,1130580001.101,3,3)
Answer must be 3-120 characters in length
"^DD",1130580001.101,1130580001.101,3,"DT")
3101012
"^DD",1130580001.101,1130580001.101,3.1,0)
QRDA MEASURE SYSTEM OID^CJ^^ ; ^S X="2.16.840.1.113883.3.249.12"
"^DD",1130580001.101,1130580001.101,3.1,.1)
QRDA SYSTEM OID (FIXED)
"^DD",1130580001.101,1130580001.101,3.1,9.01)

"^DD",1130580001.101,1130580001.101,3.1,9.1)
S X="2.16.840.1.113883.3.249.12"
"^DD",1130580001.101,1130580001.101,3.1,"DT")
3101012
"^DD",1130580001.101,1130580001.101,3.2,0)
QRDA CODE^F^^4;1^K:$L(X)>80!($L(X)<1) X
"^DD",1130580001.101,1130580001.101,3.2,.1)
QRDA MEASURE CODE
"^DD",1130580001.101,1130580001.101,3.2,3)
Answer must be 1-80 characters in length
"^DD",1130580001.101,1130580001.101,3.2,"DT")
3101012
"^DD",1130580001.101,1130580001.111,0)
VERY LONG DESCRIPTION SUB-FIELD^^.01^1
"^DD",1130580001.101,1130580001.111,0,"DT")
3101013
"^DD",1130580001.101,1130580001.111,0,"NM","VERY LONG DESCRIPTION")

"^DD",1130580001.101,1130580001.111,0,"UP")
1130580001.101
"^DD",1130580001.101,1130580001.111,.01,0)
VERY LONG DESCRIPTION^Wx^^0;1
"^DD",1130580001.101,1130580001.111,.01,.1)
LONGER DESCRIPTION - IF IT DOESN'T FIT IN .6
"^DD",1130580001.101,1130580001.111,.01,3)
LONGER DESCRIPTION - INSTEAD OF LONG DESCRIPTION
"^DD",1130580001.101,1130580001.111,.01,"DT")
3101013
"^DIC",1130580001.101,1130580001.101,0)
C0Q QUALITY MEASURE^1130580001.101
"^DIC",1130580001.101,1130580001.101,0,"GL")
^C0Q(101,
"^DIC",1130580001.101,"B","C0Q QUALITY MEASURE",1130580001.101)

**END**
**END**